Amiko Digital Health, a company based in London, UK, landed CE Mark approval for its Respiro sensors and accompany platform to be used with Teva’s Spiromax , Chiesi’s Nexthaler and GlaxoSmithKline’s Ellipta inhalers.
The Respiro system records usage of an inhaler every time it’s accessed, passing that information in real-time to a patient’s phone and onto its portal. Patients, doctors, and researchers can access and analyze the information to gain insights into how a therapy is affected and how a regimen can be improved.
The system even includes AI-powered therapy suggestions that can complement a physician or researcher.
“Respiro’s medication sensors capture data on true adherence behaviour, which better reflects real-life patient inhaler use, as compared to traditional measures of adherence” in a published statement said Dr. Job FM van Boven, assistant professor of Drug Utilization Research at the University Medical Center Groningen, The Netherlands. “This information can help us better understand the effectiveness of an inhaled drug therapy, and support the development of personalized and cost-effective interventions promoting adherence and correct inhaler technique”.
Product page: Respiro…